即用型艾司洛尔治疗危急重症患者的成本效果分析  

Cost-effectiveness analysis of ready-to-use esmolol in the treatment of critically ill patients

作　　者：谭宝滢 周柯若 林子义 郑强 姚强[3] 祝倾 任懋东 宋剑萍 解薇 宣建伟 TAN Baoying;ZHOU Keruo;LIN Ziyi;ZHENG Qiang;YAO Qiang;ZHU Qing;REN Maodong;SONG Jianping;XIE Wei;XUAN Jianwei(Institute of Pharmaceutical Economics,School of Pharmacy,Sun Yat-sen University,Guangdong Guangzhou 510006,China;School of Pharmacy,Southern Medical University,Guangdong Guangzhou 510006,China;Baxter(China)Investment Co.,Shanghai 200032,China)

机构地区：[1]中山大学药学院医药经济研究所,广东广州510006 [2]南方医科大学药学院,广东广州510006 [3]百特(中国)投资有限公司,上海200032

出　　处：《中国医院药学杂志》2024年第4期425-431,共7页Chinese Journal of Hospital Pharmacy

摘　　要：目的:评估即用型艾司洛尔对比其它非即用型超短效β受体阻滞剂治疗以室上性心动过速为代表的危急重症患者的经济性,为临床合理用药提供参考。方法:基于中国医疗卫生体系角度构建决策树模型,评估目标患者在围手术期使用即用型艾司洛尔对比使用艾司洛尔注射液或兰地洛尔的健康产出与成本。临床数据来源于中国人群的临床研究和专家调研。成本数据来源于已发表的文献和专家调研。采用单因素敏感性分析和概率敏感性分析验证结果稳健性。结果:基础分析显示,与艾司洛尔注射液相比,即用型艾司洛尔可减少0.12人次剂型相关的安全性事件发生,同时可节省203.79元,其中药品成本、医用耗材成本、生理盐水配置成本和剂型相关的安全性事件处理成本分别节省181.90,10.00,5.45和6.44元。与兰地洛尔相比,即用型艾司洛尔可减少0.04人次药物不良反应的发生,同时可节省2 347.20元,其中药品成本、医用耗材成本、生理盐水配置成本和药物不良反应处理成本分别节省2 328.40,10.00,5.45和3.35元。敏感性分析显示结果稳健。结论:相比于艾司洛尔注射液和兰地洛尔,即用型艾司洛尔治疗以室上性心动过速为代表的危急重症患者更具经济性,且有绝对优势。OBJECTIVE To evaluate the economics of ready-to-use esmolol compared with other non-ready-to-use ultra-short-actingβ-blockers for the treatment of patients with critical illnesses represented by supraventricular tachycardia and provide references for rational clinical medication.METHODS A decision tree model was constructed from the perspective of Chinese healthcare system to assess the health outcomes and costs of using ready-to-use esmolol versus esmolol injection or landiolol in the perioperative period.Clinical data were gathered from clinical studies and expert survey in the Chinese context.Cost data were derived from published literature and expert survey.One-way sensitivity analysis and probabilistic sensitivity analysis were conducted to validate the robustness of the results.RESULTS The primary analysis indicated that compared to esmolol in glass ampoule form,ready-to-use esmolol led to a 0.12 times reduction in the occurrence of dosage form-related safety events,resulting in cost savings of 203.79 CNY.This included 181.90 CNY savings in drug costs,10.00 CNY in medical consumables costs,5.45 CNY in saline configuration costs,and 6.44 CNY in dosage form-related safety event management costs,respectively.In comparison to landiolol,ready-to-use esmolol reduced the occurrence of adverse drug reactions by 0.04 times,resulting in cost savings of 2347.20 CNY.This included 2328.40 CNY in drug costs,10.00 CNY in medical consumables costs,5.45 CNY in saline configuration costs,and 3.35 CNY in costs related to adverse drug reaction treatment.Sensitivity analysis confirmed the robustness of the results.CONCLUSION Compared to esmolol in glass ampoule form and landiolol,ready-to-use esmolol is more economical and has a definite advantage in the treatment of critically ill patients represented by supraventricular tachycardia.

关 键 词：盐酸艾司洛尔氯化钠注射液(即用型) 盐酸艾司洛尔注射液 注射用盐酸兰地洛尔 快速心律失常 围手术期高血压 成本效果分析 

分 类 号：R956[医药卫生—药学]